EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Product updates
DeepCure announces breakthrough robotic synthesis for turning complex drugs into testable molecules
AI Drug Discovery
May 28, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Partnerships
Product updates
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
AI Drug Discovery

AI Drug Discovery

May 28, 2024

DeepCure announces breakthrough robotic synthesis for turning complex drugs into testable molecules

Product updates

  • AI-powered small-molecule drug developer DeepCure has announced a chemical synthesis breakthrough in its proprietary Inspired Chemistry platform, which is designed to automatically synthesize thousands of complex molecules simultaneously, such as multiple chiral centers.

  • The platform is available to early access partners, enabling researchers to synthesize and test more diverse and complex molecule designs rapidly. A recent study has demonstrated the synthesizing of nirmatrelvir, an orally active 3C-like protease inhibitor, and 56 analogs parallelly in a robot-driven workflow. Key features of the product include AI-driven software for small-molecule design, the use of common laboratory instruments and robots, and the capacity to handle about 28 different reaction types currently. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.